/cloudfront-us-east-2.images.arcpublishing.com/reuters/JFIWHHL7V5I3HPR2TATCJCKGNA.jpg)
US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
Some leading U.S. obesity specialists say they expect Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s (NOVOb.CO) popular Wegovy as they belong to the same class of medicines. Key Points
ReutersWhat to know about Eli Lilly's new obesity drug
The U.S. Food and Drug Administration approved Eli Lilly's (LLY.N) keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's (NOVOb.CO) popular weight-loss therapy Wegovy. Key Points
ReutersTirzepatide, another diabetes drug cleared for weight loss in US, yet to get regulator nod in India
In clinical trials, tirzepatide by Eli Lilly has shown to reduce body weight by up to 22.5 percent, on average, after about 72 weeks, according to the company. Key Points
ThePrintWeight loss from Eli Lilly’s Zepbound reversed slowly after treatment stopped
People who stopped taking Eli Lilly & Co.’s Zepbound after about eight months regained half the weight they’d lost a year later, as per a study. | Health Key Points
Hindustan TimesEli Lilly's obesity drug now available in U.S. pharmacies
Eli Lilly's (LLY.N) recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost customers whose health insurance does not cover the drug $550 a month, or half the list price, the company said on Tuesday. Key Points
Reuters
Lilly weight-loss drug Zepbound gets US, UK approval to rival Wegovy
U.S. and UK regulators both gave thumbs up to Eli Lilly's weight-loss treatment. The drugs are the most effective treatments for weight loss approved to date. | Health Key Points
Hindustan Times